Provides technology, data and commercial services to help life-sciences and pharma companies market and launch drugs.
Provides technology, data and commercial services to help life-sciences and pharma companies market and launch drugs.
Charges fees to drugmakers for work done by its own staff and platforms, from content creation and sales-and-marketing operations to regulatory documentation, usually under multi-year contracts. The US is its largest market. It listed on the Indian stock market in 2024.
In one line: A life-sciences-focused digital/commercial services firm.
Moat: narrow (process know-how, switching costs). Deep life-sciences domain expertise and embedded workflows create switching costs versus generic IT vendors.
Headquarters: Bengaluru, India · Founded: 1998 · Employees: 5,175
Size Indegene (INDGN.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.69B, the 429th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹654.95 on 18 Nov 2026.
Performance Over six months the shares gained 28.1%, against -3.0% for the median peer and +3.8% for the India market (cap-weighted) — 3rd highest of 20 in its peer set.
Growth Revenue grew 35.8% over the last twelve months (peer median +6.8%); the operating margin is 12.4% (peer median 12.0%).
Valuation It trades at 29.5× forward earnings against a peer median of 21.4× (5th most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 31% a year for seven years (Req g). Recent delivered growth is +29%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.1 points above its cost of capital (15.9% WACC).
Next results Next results expected around 29 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹41.3B | ₹35.1B | ₹28.4B | ₹25.9B | ₹23.1B |
| Revenue growth | — | +24% | +10% | +12% | — |
| Gross profit | ₹5.11B | ₹8.79B | ₹7.72B | ₹6.94B | ₹5.81B |
| EBITDA | ₹6.83B | ₹6.27B | ₹5.38B | ₹5.14B | ₹3.99B |
| Net income | ₹4.11B | ₹4.01B | ₹4.07B | ₹3.37B | ₹2.66B |
| Free cash flow | n/a | ₹6.19B | ₹4.61B | ₹4.92B | ₹1.00B |
| Capital expenditure | n/a | ₹443M | ₹300M | ₹107M | ₹188M |
| Total debt | ₹1.57B | ₹1.44B | ₹1.02B | ₹4.90B | ₹5.03B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Indegene INDGN.NS | $1.69B | +28% | +36% | 12% | 29.5× | 31.4% |
| Iqvia IQV | $42.5B | +50% | +9% | 14% | 18.7× | 16.8% |
| Accenture ACN | $134B | +27% | +6% | 15% | 15.5× | 1.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | INDGN.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +11.3% | -3.9% | 3rd highest of 21 |
| 6-month return | +28.1% | -3.0% | 3rd highest of 20 |
| Distance from 52-week high | -3.3% | -35.8% | highest of 21 |
| Revenue growth (TTM) | +35.8% | +6.8% | 3rd highest of 20 |
| Operating margin | 12.4% | 12.0% | 10th highest of 20 |
| Forward P/E | 29.5× | 21.4× | 5th most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 31.4% | 15.6% | 4th most demanding of 17 |
| Growth delivered (Del g) | +29.4% | +8.7% | 2nd highest of 17 |
| Hurdle (Req g minus delivered) | +2.0 pp | +4.5 pp | 9th least demanding of 17 |
| ROIC minus cost of capital | +1.1 pp | -1.3 pp | 10th highest of 21 |
| EV / EBITDA | 21.5× | 21.4× | 4th most expensive of 8 |
| Net debt / EBITDA | -1.6× | -0.7× | 3rd least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Indegene INDGN.NS | India | $1.69B | +28% | +36% | 12% | 29.5× | 31.4% | +29.4% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.70B | +2% | +7% | 17% | 17.0× | -3.5% | +6.8% |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.70B | +2% | +17% | 31% | 21.4× | 24.3% | +15.7% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.70B | -36% | -28% | -50% | 22.0× | 11.3% | -11.0% |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.67B | -12% | +7% | 39% | 26.3× | 18.4% | +10.8% |
| Faes Farma FAE.MC | Spain | $1.71B | +6% | +32% | 14% | 17.4× | 3.7% | +9.9% |
| Maze Therapeutics MAZE | United States | $1.71B | +27% | -100% | -821% | n/a | n/a | n/a |
| BrightGene Bio-Medical Technology 688166.SS | China | $1.71B | -57% | +14% | 7% | 74.9× | 35.3% | +9.2% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| NATCO Pharma NATCOPHARM.NS | India | $1.73B | -27% | -30% | 17% | 19.1× | 20.5% | +19.0% |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +8% | +15% | 35% | 9.2× | -14.9% | +13.5% |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $1.62B | -47% | -18% | 9% | n/a | 33.0% | +0.9% |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.62B | -30% | +30% | 10% | n/a | 42.4% | +23.0% |
| Agios Pharmaceuticals AGIO | United States | $1.78B | +4% | +214% | -298% | n/a | n/a | n/a |
| Shenzhen Hepalink Pharmaceutical 9989.HK | Hong Kong | $1.78B | -13% | -1% | 8% | 8.7× | -0.4% | -0.2% |
| Anupam Rasayan India ANURAS.NS | India | $1.61B | -3% | +24% | 16% | 49.9× | n/a | n/a |
| Harbin Pharmaceutical 600664.SS | China | $1.78B | +32% | +2% | 5% | 19.7× | -5.3% | +8.2% |
| Sino Biological 301047.SZ | China | $1.60B | +27% | +20% | 17% | 51.6× | 31.1% | -15.1% |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.60B | -31% | -13% | 12% | 57.4× | 12.8% | -14.0% |
| Eton Pharmaceuticals ETON | United States | $1.79B | +226% | +101% | 29% | 24.6× | 21.9% | +359.6% |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.59B | -14% | -13% | 6% | 12.6× | -6.6% | -5.6% |